Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies

BACKGROUND AND OBJECTIVE: The interleukin-36 signalling pathway is associated with pathogenesis of a number of inflammatory diseases. Spesolimab is a selective, humanised, IgG1 antibody that targets the interleukin-36 receptor. We aimed to evaluate the pharmacokinetics, safety and tolerability of si...

Descripción completa

Detalles Bibliográficos
Autores principales: Joseph, David, Thoma, Christian, Haeufel, Thomas, Li, Xiujiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734218/
https://www.ncbi.nlm.nih.gov/pubmed/36451029
http://dx.doi.org/10.1007/s40262-022-01176-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734218/
https://www.ncbi.nlm.nih.gov/pubmed/36451029
http://dx.doi.org/10.1007/s40262-022-01176-5

Ejemplares similares